IDH2 mutations in acute myeloid leukemia
R Babakhanlou, C DiNardo, G Borthakur - Leukemia & Lymphoma, 2023 - Taylor & Francis
Advances in the treatment of acute myeloid leukemia (AML) over the last 40 years have
been limited. With an improved understanding of the pathophysiology of the disease, the …
been limited. With an improved understanding of the pathophysiology of the disease, the …
[HTML][HTML] Neutropenic enterocolitis: an uncommon, but fearsome complication of leukemia
R Babakhanlou, F Ravandi-Kashani… - Journal of …, 2023 - ncbi.nlm.nih.gov
Neutropenic enterocolitis (NEC) is a life-threatening condition occurring in severely
neutropenic patients, following intensive chemotherapy for leukemia. Its pathogenesis is not …
neutropenic patients, following intensive chemotherapy for leukemia. Its pathogenesis is not …
[HTML][HTML] Anorectal Infections in Neutropenic Leukemia Patients: A Common Clinical Challenge
R Babakhanlou, F Ravandi-Kashani, AG Hita… - Journal of …, 2024 - ncbi.nlm.nih.gov
Anorectal infections in neutropenic leukemia patients are a significant and potentially life-
threatening complication. The pathogenesis of this condition is not entirely understood and …
threatening complication. The pathogenesis of this condition is not entirely understood and …
Comparison of low dose cytosine arabinoside, azacitidine and azacitidine venetoclax combination treatment as remission induction in elderly acute myeloid leukemia …
F Can, A Yıkılmaz, D Gokce, T Güney… - Journal of Medicine …, 2021 - dergipark.org.tr
Aims: Low-intensity therapies are widely preferred in the treatment of advanced age, fragile
acute myeloid leukemia (AML) patients. In this study, we aimed to compare hematological …
acute myeloid leukemia (AML) patients. In this study, we aimed to compare hematological …